Also trades as: NRSN (NASDAQ) · $vol 0M
NRSNW NASDAQ
NeuroSense Therapeutics Ltd.
1W: -55.6%
1M: +1.3%
3M: -72.4%
YTD: -86.7%
1Y: -93.7%
3Y: -88.2%
$0.04
-0.01 (-11.11%)
Weekly Expected Move ±85.5%
$-0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$22K
+77.3% ▲
Operating Income
-$10M
+17.8% ▲
Net Income
-$10M
-1.0% ▼
EPS (Diluted)
$-0.55
+33.7% ▲
EBITDA
-$10M
-2.5% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $3K | $3K | $89K | $97K | $22K |
| Gross Profit | -$3K | -$3K | -$89K | -$97K | -$22K |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $2M | $3M | $6M | $7M | $6M |
| SG&A Expenses | $393K | $3M | $7M | $5M | $4M |
| Operating Expenses | $3M | $6M | $13M | $12M | $10M |
| Operating Income | -$3M | -$6M | -$14M | -$12M | -$10M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $1M | $15K | $550K | $311K |
| Income Before Tax | -$3M | -$4M | -$12M | -$11M | -$10M |
| Tax Expense | $0 | $0 | -$1M | $0 | $0 |
| Net Income | -$3M | -$4M | -$12M | -$10M | -$10M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-0.51 | $-0.23 | $-1.07 | $-0.83 | $-0.55 |
| EBITDA | -$3M | -$3M | -$12M | -$10M | -$10M |
| Shares Outstanding | 6M | 11M | 12M | 14M | 19M |